Identifying dosage sensitive genes is a key to understand the mechanisms 27 underlying intellectual disability in Down syndrome (DS). The Dp(17Abcg1-Cbs)1Yah 28 DS mouse model (Dp1Yah) show cognitive phenotype and needs to be investigated 29 to identify the main genetic driver. Here, we report that, in the Dp1Yah mice, 3 copies 30 of the Cystathionine-beta-synthase gene (Cbs) are necessary to observe a deficit in 31 the novel object recognition (NOR) paradigm. Moreover, the overexpression of Cbs 32 alone is sufficient to induce NOR deficit. Accordingly targeting the overexpression of 33 human CBS, specifically in Camk2a-expressing neurons, leads to impaired objects 34 discrimination. Altogether this shows that Cbs overdosage is involved in DS learning 35 and memory phenotypes. In order to go further, we identified compounds that interfere 36 with the phenotypical consequence of CBS overdosage in yeast. Pharmacological 37 intervention in the Tg(CBS) with one selected compound restored memory in the novel 38 object recognition. In addition, using a genetic approach, we demonstrated an epistatic 39 interaction between Cbs and Dyrk1a, another human chromosome 21 gene encoding 40 the dual-specificity tyrosine phosphorylation-regulated kinase 1a and an already 41 3 known target for DS therapeutic intervention. Further analysis using proteomic 42 approaches highlighted several pathways, including synaptic transmission, cell 43 projection morphogenesis, and actin cytoskeleton, that are affected by DYRK1A and 44 CBS overexpression. Overall we demonstrated that CBS overdosage underpins the 45 DS-related recognition memory deficit and that both CBS and DYRK1A interact to 46 control accurate memory processes in DS. In addition, our study establishes CBS as 47 63 Down Syndrome (DS) is the most common aneuploidy observed in human. The 64 presence of an extra copy of the Human chromosome 21 (Hsa21; Hsa for Homo 65 sapiens) is associated with intellectual disabilities and several morphological and 66 physiological features. Phenotypic mapping in human with partial duplication 67 highlighted the contribution of several regions of the Hsa21 in DS features (1, 2). 68 Additional information was collected from trisomic and monosomic mouse models to 69 detect genomic regions sensitive to dosage and able to induce impairments in 70 behaviour and other DS related traits (3-11). Most of the efforts focused on the region 71 homologous to the Hsa21 located on mouse chromosome 16 (Mmu16; Mmu for Mus 72 Musculus), highlighting the contribution of the Amyloid precursor protein (App) (12), of 73 the Glutamate receptor, ionotropic, kainate 1 (Grik1) or of the dual-specificity tyrosine 74 phosphorylation-regulated kinase 1a (Dyrk1a) (13, 14) overdosage to DS cognitive 75 defects. At present, DYRK1A is a main target for therapeutic intervention with a few 76 compounds inhibiting the protein kinase activity, improving mainly cognition in DS 77 mouse models (15-20). However, models carrying trisomy of the region of Mmu17 78
an intervention point for treating intellectual deficiencies linked to DS. 48 49 SIGNIFICANT STATEMENT 50 Here, we investigated a region homologous to Hsa21 and located on mouse 51 chromosome 17. We demonstrated using three independent genetic approaches that 52 the overdosage of the Cystathionine-beta-synthase gene (Cbs) gene, encoded in the 53 segment, is necessary and sufficient to induce deficit in novel object recognition (NR) . 54
In addition, we identified compounds that interfere with the phenotypical 55 consequence of CBS overdosage in yeast and in mouse transgenic lines. Then we 56 analyzed the relation between Cbs overdosage and the consequence of DYRK1a 57 overexpression, a main driver of another region homologous to Hsa21 and we 58 demonstrated that an epistatic interaction exist between Cbs and Dyrk1a affecting 59 different pathways, including synaptic transmission, cell projection morphogenesis, 60 and actin cytoskeleton. 61 62 INTRODUCTION 5 Tc1/Ms2Yah mice (25) . Similarly the trisomy of a larger overlapping segment on 87
Mmu17 from Abcg1 to Rrp1b induces an increased LTP as compared to control in the 88 Dp(17)Yey model (22) and was shown to genetically interact with the trisomy of the 89
Lipi-Zbtb21 interval. More specifically the trisomy of both this Abcg1-Rrp1b region and 90 the Cbr1-Fam3b region was detrimental for learning and memory in the Morris water 91 maze and for LTP in DS mouse models (23) . 92
Among the 11 trisomic genes in the Dp1Yah model, the cystathionine-beta-93 synthase gene, Cbs, encodes a pyridoxal phosphate-dependent enzyme converting 94 homocysteine to cystathionine. This first step of the transulfuration pathway removes 95 homocysteine from the methionine cycle thereby also affecting the folate and the 96 methylation pathways, while contributing to the cysteine cycle. Of note, in human, 97 homozygous loss-of-function mutations in CBS are associated with homocystinuria 98 (OMIN236200) a metabolic condition with intellectual disability. CBS is also the major 99 enzyme catalysing the production of H2S from L-cysteine (26) or from the condensation 100 of homocysteine with cysteine (27). H2S is now considered a major gaseotransmitter 101 in the brain (28) and interferes with synaptic transmission. Considering the upregulated 102 expression of CBS in several brain regions of the Dp1Yah model and its impact on 103 intellectual disability, we decided to focus on Cbs and decipher the role of CBS in DS 104 cognitive phenotypes. To this end, we generated and characterized constitutive and 105 conditional changes in Cbs dosage in the nervous system of various mouse models. 106
In addition we selected pharmacological drugs able to counteract the phenotypical 107 consequence of CBS overexpression, in particular behavioural impairments, and finally 108 further and its supporting annexes entered into legislation 01 February 2013) relative to the 118 protection of animals used in scientific experimentation. YH was granted the 119 accreditation 67-369 to perform the reported experiments in the animal facility 120 . For all these tests, mice were kept in Specific Pathogen free 121 conditions with free access to food and water. The light cycle was controlled as 12 h 122 light and 12 h dark (lights on at 7AM). All the behavioural tests were done between 123 9:00 AM and 4:00 PM. 124
Several mouse lines were used to decipher the influence of Cbs: the trisomic 125 mouse model, Dp(17Abcg1-Cbs)1Yah, named here Dp1Yah, carries a segmental 126 duplication of the Abcg1-Cbs region of the Mmu17 (21) kept on the C57BL/6J; the 127 inactivated allele of C57BL/6J.Cbs tm1Unc (29); and the PAC transgenic line 128 Tg(CBS)11181Eri (named here Tg(CBS)), originally identified as 60.4P102D1 (30) and 129 backcrossed on C57BL/6J for more than 7 generations. We designed, generated and 130 8 loxP-gfp-loxP interrupting cassette ( Figure 3A ) on C57BL/6J background. We used the 135 transgenic Tg(Camk2a-cre)4Gsc mouse line (31), named here Tg(Camk2a-cre), and 136 bred further on C57BL/6J, as a glutamatergic neuron-specific Cre driver. The Dyrk1a 137 BAC transgenic mouse line, named here Tg(Dyrk1a) was generated previously in our 138 lab (32). All lines were generated and bred on the C57BL/6J genetic. The genotype 139 identification was done from genomic DNA isolated from tail biopsies with specific PCR 140 reaction ( Supplementary table 1) . 141
Behavioural analysis 142
The sample size was estimated according to our similar experiments done 143 previously while investigating behaviour in DS mouse models (5, 25, 33) . To 144 investigate the role of Cbs in the Dp1Yah cognitive phenotypes, we generated 2 145 independent cohorts (cohort 1 (C1): wild type (wt) littermates n=11; Cbs tm1Unc/+ , n=8; 146 Dp1Yah, n=8; Dp1Yah/Cbs tm1Unc , n=11; and cohort 2 (C2): wt littermates n=18; 147 Cbs tm1Unc/+ , n=15; Dp1Yah, n=15; Dp1Yah/Cbs tm1Unc , n=10). All cohorts were evaluated 148 in the open field (C1: 33 weeks; C2: 14-16 weeks), Novel Object Recognition (NOR) 149 (C1: 33 weeks; C2:14-16 weeks) in adult mice. In addition we performed the Y maze 150 (C2: 15-19 weeks) and the rotarod tests (C2: 25-28 weeks of age). 151
Wild-type littermates (n=13) and Tg(CBS)/0 (n=17) hemizygotes were tested for 152 circadian actimetry (14 weeks), Y Maze (16 weeks), open field (17 weeks) and NOR 153 (17 weeks). We added an additional group of wt (n=9) and Tg(CBS)/0 (n=10) to 154 validate the results from the NOR; animals were tested at the same age (17 weeks). A 155 cohort with 4 genotypes (wt (n=13), Tg(Camk2-Cre)/0 (n=11), Tg(Prp-gfp-CBS)/0 156 (n=12), and Tg(Camk2-Cre)/0;Tg(Prp-gfp-CBS)/0 (n=14)) was evaluated through the 9 same behavioural tests with rotarod (14 weeks), Y maze (16 weeks Xho1 restriction sites) and subcloned in the high copy number 2 µ-derived vectors 175 p424-GPD and p426-GPD, each time under the control of the strong constitutive GDP 176 promoter (34). Transformation of yeast cells was performed using a standard lithium 177 acetate method (35). 178
The yeast strain used in this study is derived from the W303 WT strain: MATa, 179 leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 For the drug screening, yeast cells were grown in uracil-and tryptophan-free 186 minimal liquid medium (SD-Ura/Trp) in overnight liquid cultures at 29 °C. The following 187 day, cells were diluted to OD600~0.2 in in fresh medium and grown for 4 hours to reach 188 exponential phase. Then three hundred and fifty microliters of exponentially growing 189 yeast cells overexpressing Cys4, adjusted to an OD600 of 0.5, were spread 190 homogeneously with sterile glass beads (a mix of ∼1.5 and 3 mm diameter) on a square 191 Petri dish (12 cm × 12cm) containing uracil-, tryptophan-and methionine-free minimal 192 agar-based solid medium (SD-Ura/Trp/Met) containing 2% (w/v) serine. Sterile filters 193 (Thermo Fisher similar to those used for antibiograms) were placed on the agar 194 surface, and 2 μl of individual compound from the various chemical libraries were 195 applied to each filter. In addition, for each Petri plate, DMSO, the vehicle, was added 196 as a negative control on the top left filter, and 2 nmol of methionine as a positive control 197 on the bottom right filter. Plates were then incubated at 33 °C for 3 days and scanned 198 using a Snap Scan1212 (Agfa). 199
Two repurposed drug libraries were screened: the Prestwick Chemical Library® 200 (1200 drugs) and the BIOMOL's FDA Approved Drug Library (Enzo Life Sciences, 640 201 drugs). In addition, the Prestwick Phytochemical library (691 green compounds, most 202 of them being in use in Human) was also screened. The compounds were supplied in 203 96-well plates as 10 mM (for the two Prestwick® libraries) and 2 mg/ml (BIOLMOL®) 204
RESULTS 274
Three copies of Cbs are necessary to induce cognitive impairments in the 275
Dp1Yah mice. 276
In order to challenge the hypothesis that three copies of Cbs are necessary to 277 induce behavioural deficits in the Dp1Yah mice, we combined the Dp1Yah mice with 278 the Cbs tm1Unc/+ knock-out model (29) Then we tested the object memory. No difference was observed during the 307 exploration of the familiar object in the presentation phase of the test ( Figure 1D top 308 left panel). However, during the discrimination phase, after 1h of retention, the Dp1Yah 309 mutant mice were not able to differentiate the familiar versus the novel object whereas 310 the wt, Cbs tm1Unc/+ and the Dp1Yah/Cbs tm1Unc spent significantly more time on the new 311 object compared to the familiar one ( Figure 1D , left bottom panel; two ways ANOVA, 312 variables "genotype" and "objects": F(3;56)= 2.86 with p=0.045; post hoc Tuckey 313 method wt "fam vs new" q= 4.885 and p= 0.001; Cbs tm1Unc/+ q= 3.913 and p= 0.008; 314 Dp1Yah, q= 0,503 and p= 0.724; Dp1Yah/Cbs tm1Unc/+ q= 4.715 and p= 0.002). 315 Accordingly, the recognition index showed that the restoration of two functional copies 316 of Cbs in the Dp1Yah mice rescued memory performance in object recognition (Figure 317 Figure 3B ). We chose the Tg(Camk2a-cre) (31), to direct the cre expression in the 358 cortical and hippocampal glutamatergic neurons and we verified the expression of the 359 human CBS in different brain regions of the double transgenic (Tg(Prp-gfp-360 CBS)/0;Tg(Camk2a-cre)/0). As expected we found expression levels comparable to 361 the endogenous murine Cbs gene in cerebellum while human CBS was overexpressed 362 in the hippocampus and the cortex ( Figure 3C ). Littermate animals carrying wt, the two 363 single transgenic constructs and the two transgenes were produced and tested for 364 object recognition. During the test, the control groups, namely wt, Tg(Prp-gfp-CBS)/0 365 and Tg(Camk2a-cre)/0, spent more time on the new object (No) than the familiar one 366 CBS is a new gene whose overdosage alters cognition in DS mouse models and as a 395 consequence is likely to contribute to DS phenotypes. 396
Identification of drugs that suppress the effects of Cys4/CBS overexpression 397 both in yeast and mouse 398
A few studies have reported the identification of CBS inhibitors (39-44) but most 399 of them were based on in vitro assays using a recombinant CBS enzyme as a drug 400 target and led to the isolation of inhibitors with relatively low potency and limited 401 selectivity, hence leading to the idea that CBS may be an undruggable enzyme. 402
Therefore we oriented toward an in cellulo phenotype-based assay that would allow 403 screening drugs that interfere with the phenotypical consequences of CBS 404 overexpression and thereby that do not necessarily directly target the CBS enzyme. 405
The budding yeast Saccharomyces cerevisiae contains a functional homolog of CBS 406 and has been shown to be a relevant system to model pathophysiological mechanisms 407 involved in a number of human disorders and to perform chemobiological approaches 408 that aim at identifying both drugs and new therapeutic targets (45-51). We thus decided 409
to create a yeast model in which the phenotypical consequences of CBS 410 overexpression may be easily and conveniently monitored in order to get a potential in 411 cellulo high throughput drug screening procedure. We reasoned that if we 412 overexpressed CBS at a sufficient level, this should lead to a decreased intracellular 413 level of methionine, similarly to what was shown in patients, and therefore that yeast 414 cells would become methionine auxotroph and thereby unable to grow on methionine-415 free minimal media. As the human CBS protein is not very stable in yeast cells and 416 20 therefore cannot be expressed at high levels (52), we decided to overexpress Cys4p, 417 the CBS homolog in S. cerevisiae. Cys4p presents the same domains and domain 418 organization than CBS apart from the N-terminal heme-binding domain which is absent 419 in the yeast protein (53). To get a degree of methionine auxotrophy sufficient to allow 420 an efficient screening, we expressed Cys4 from the strong constitutive GPD promoter 421 from two different high copy number 2 µ vectors (each present at ~50 copies per cell) 422 and supplement the growth medium with serine, which is one of the Cys4p/CBS 423 substrates that could otherwise become limiting upon Cys4 overexpression (Figure  424 4A). 425
Using this model, we tested ≈ 2200 compounds from 3 different chemical 426 libraries consisting mainly of repurposed drugs for their ability to suppress the 427 methionine auxotrophy induced by Cys4p overexpression. We exploited a similar 428 principle as a yeast-based screening setup previously (46, 47, 49, 54) . Briefly, we 429 spread, on a solid agar-based methionine-free minimal medium, yeast cells 430 overexpressing Cys4. Then we put filters on the agar surface and add different drugs 431 from chemical libraries on each filters. After 3 days of incubation at 33°c, active 432 compounds were identified by a halo of restored/enhanced growth around the filter on 433 which they were loaded ( Figure 4B ). The advantage of this method is that, in one 434 simple experiment, it allows numerous compounds to be tested across a large range 435 of concentrations due to the diffusion of the molecule in the medium surrounding the 436 filter onto which it was deposited. This design drastically improves the sensitivity of the 437 screen because the screened compounds can be toxic at high concentrations whereas 438 being active at subtoxic concentrations. We identified four different compounds, among 439 which disulfiram (DSF, Figure 4C) . 440 21 Next we tested if DSF was able to restore the object recognition of the mouse 441 model overexpressing human CBS. Three independent cohorts of Tg(CBS) and control 442 littermates were treated with DSF (10mg/kg/day) for 10 days before being tested for 443 the novel object recognition. As shown in figure 4D , DSF-treated transgenic animals 444 were restored in the novel object recognition paradigm whereas non treated mutant 445 animals were still not able to discriminate the new versus the familiar object. 446
Interestingly the wt treated individuals were no more able to perform the discrimination 447 while the vehicle treated controls were able to do so ( we tested the Novel Object Recognition memory after 1h of retention ( Figure 5C ). As 479 expected, the 2 single mutants were impaired (Two ways ANOVA, variables 480 "genotype" and "objects": F(3;70)=7.09 with p<0.001, post hoc Tukey Test: Dp1Yah 481 "fam vs new" q=1.333 and p=0.349; Tg(Dyr1a) q=1.732 and p=0.225 -Recognition 482 Index: One sample t-test mean vs 50%: Dp1Yah p=0.253; Tg(Dyrk1a) p=497) but the 483 double transgenic mice Dp1Yah/Tg(Dyrk1a) were able to discriminate the novel object 484 as wt littermates (Two ways ANOVA, variables "genotype" and "objects": F(3;70)=7.09 485 with p<0.001, post hoc Tukey Test: wt "fam vs new" q=4.543 and p=0.002; 486
Dp1Yah/Tg(Dyr1a) q=5.289 and p<0.001 -Recognition Index: One sample t-test: wt 487 23 p=0.048; Dp1Yah/Tg(Dyrk1a) p=0.011), suggesting that the effects of Dyrk1a 488 overexpression are compensated by 3 copies of the Abcg1-Cbs region. 489
Lastly we checked the learning and spatial memories using the Morris Water 490 Maze task, followed by a probe test 24h after the learning period ( Figure 5D ). Even if 491 all the groups increased their performance during the learning phase for reaching the 492 platform after 6 days of training (J1-J6), wt and Dp1Yah mice found the platform with 493 lower latency than the Tg(Dyrk1a) and Dp1Yah/Tg (Dyrk1a) 
Proteomics unravels complex intermingled proteomic changes influenced by 506

DYRK1A overexpression and by Dp1Yah trisomic genes 507
In order to unravel the impact of CBS and DYRK1A on cellular mechanism within 508 the hippocampus that could lead to the memory phenotype observed in the novel 509 object recognition (NOR) test, we profiled the proteome in the hippocampi isolated from 510 24 Dp1Yah, Tg(Dyrk1a) and double (Dp1Yah,Tg(Dyrk1a)) animals, and compared them 511 to the wt control littermates. We collected the samples after the behavioral evaluation 512 and performed a Tandem Mass Tag labeling (Thermo Scientific, Illkirch) followed by 513 LC-MS/MS orbitrap analysis. We were able to detect 1655 proteins of which 546 were 514 detected in all the 3 genotypes with a variability below 40% (Supplementary table 3) , 515 and among which 338 proteins were expressed at the same level as control ones. A 516 total of 208 proteins were found differentially expressed with levels of expression 517 above 1.2 (206) or below 0.8 (2) in Dp1Yah, Tg(Dyrk1a) and double mutant mice 518 ( Figure 6A ). Nine proteins were upregulated in all 3 genotypes: the RIKEN cDNA 519 6430548M08 gene product (6430548M08RIK), Actin related protein 2/3 complex, 520 subunit 1A (ARPC1A), Bridging Integrator 1 (BIN1), the Family with sequence similarity 521 213, member A (Fam213a), Glyoxalase 1 (GLO1), Importin 5 (LPO5), NADH 522 dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1), Prostaglandin reductase 2 523 (PTGR2) and Synaptosomal-associated protein 25 (SNAP25). Toppcluster analysis of 524 the protein content unraveled a general common network with interacting proteins 525 modified by the 3 genetic conditions ( Figure 6B-C) . Functional analysis using gene 526 ontology highlighted several cellular components affected in the 3 genotypes including 527 synaptic particles, neuron projection, presynapse/synapse, axon, myelin sheath and 528 different types of vesicles (Supplementary table 4) . Cell/neuron projection 529 development, morphogenesis, and differentiation, as well as secretion, synaptic and 530 anterograde trans-synaptic signaling were affected in Dp1Yah while aldehyde 531 catabolic processes and regulation of anatomical structure size were modified in 532 Tg(Dyrk1a). Interestingly all these biological process were not be disturbed in double 533 transgenic animals. Likewise molecular functions controlling ubiquitin protein ligase, 534 calcium ion binding and dicarboxylic acid transmembrane transporter activity in 535 25 Dp1Yah, or cytoskeletal protein and myosin binding in Tg(Dyrk1a) were restored 536 (Dp1Yah,Tg(Dyrk1a)). On the contrary oxidoreductase activity was newly modified in 537 the double transgenic hippocampi. 538
We selected three proteins with different proteomic profiles in hippocampi and 539 studied their expression in another brain region, the cerebral cortex, using western blot 540 analysis: The alpha synuclein (SNCA), the Fused in sarcoma (FUS) that are 541 associated with neurodegenerative disease (59-62) and the synaptosomal-associated 542 protein 25 (SNAP25), a component of the SNARE complex involved in calcium-543 triggered exocytosis (63-65). As shown in figure 5D , levels of SNCA were similar to wt 544 level. We did observe increased amount of this protein in the (Dp1Yah,Tg(Dyrk1a)) 545 animals contrary to what was observed in the proteome analysis. The presynaptic 546 SNAP25 protein was significantly up-regulated in cortical regions of the 547 (Dp1Yah,Tg(Dyrk1a)) animals and to a lesser extent in the Dp1Yah and Tg(Dyrk1a) 548 ones (student t-test wt versus Tg(Dyrk1a) p=0,233; wt versus Dp1Yah p=0,06; wt 549 versus D1Yah/Tg(Dyrk1a) p=0,02). Hence, in the proteomic approach, we also 550 observed the increase previously detected in the hippocampus of those three 551 transgenic lines. The RNA-binding protein FUS was found overexpressed in the 552 Dp1Yah brains and to a lesser extent in the (Dp1Yah,Tg (Dyrk1a) In this report we demonstrated that the genetic overdosage of Cbs is necessary 558 and sufficient to induce defective novel object recognition in 3 different types of DS 559 models. CBS overdosage is certainly the main driver of the learning and memory 560 phenotypes detected previously in DS models for the Mmu17 region (22, 33) but we 561 cannot rule out the possibility that one or more other gene(s) contribute with Cbs to the 562 phenotype. Previous analysis of CBS overdosage with the same transgenic line 563 Tg(CBS) on the FVB/N genetic background showed no change in fear learning task 564 and locomotor activity but increased LTP-dependent synaptic plasticity (66); a 565 phenomenon also detected in vitro and in vivo in other DS models where Cbs is 566 trisomic in the C57BL/6J genetic background (22, 33) . Nevertheless no positive effect 567 on cognition is associated with increase CBS dosage as previously proposed by 568 Régnier et al. (66) . Instead the overdosage of CBS always impairs the hippocampal-569 dependent novel object recognition test suggesting that increased synaptic plasticity 570 found in Cbs trisomic models may alter synaptic functions. Increased synaptic plasticity 571 could occur via increased H2S as it has been shown that H2S facilitates LTP by 572 stimulating the post-synaptic NMDA receptors (67, 68). Moreover, a role of H2S has 573 been foreseen in calcium homeostasis regulation which is also crucial for neuronal 574 synaptic plasticity (69). 575 DSF was isolated from a drug screening performed in yeast cells 576 overexpressing CBS homolog Cys4p and looking for drugs counteracting its effect on 577 methionine auxotrophy. Although DSF has been first identified as an inhibitor of 578 mitochondrial aldehyde dehydrogenase (ALDH) (70), it is a relatively nontoxic 579 substance, which has been on the market for more than 40 years to support the 580 treatment of chronic alcoholism by producing an acute sensitivity to ethanol, thanks to 581 its ability to inhibit aldehyde dehydrogenases, thus leading to an accumulation of 582 acetaldehyde in blood when alcohol is ingested. As acetaldehyde is responsible for 583 many of the unpleasant effects that follow ingestion of large quantities of alcohol 584 ("hangover"), DSF treatment discourages the patients to sustain a regular alcohol 585 consumption by exacerbating and accelerating its unpleasant side effects. Our 586 preliminary data about the mechanism of action of DSF suggest that this molecule may 587 not directly inhibit CBS enzymatic activity but probably rather acts on the cellular 588 consequences of CBS overexpression. The assay used for the screening, in principle, 589 leads to the isolation of drugs acting both directly or not on CBS/Cys4. This latter point 590 is of importance given that CBS may not be a druggable target enzyme. And indeed, 591 at present, we do not know if the DSF is acting directly or indirectly on CBS but we 592 must assume the function altered by CBS overdosage, whatever it is, is conserved and 593 similarly sensitive to DSF treatment in both yeast and mouse. Of note, upon absorption 594 DSF is rapidly reduced to diethyldithiocarbamate (DDC), which then reacts with thiol 595 groups. Both DSF and DCC are potent copper chelators, thereby possibly affecting the 596 activity of copper-dependent enzymes such as monooxygenases, the Cu-Zn 597 superoxide dismutase, amine oxidase, ADN methyltransferases and cytochrome 598 oxidase. As a result, DSF has been shown to affect various cellular processes such as 599 cocaine metabolism and catecholamine synthesis, and proteasome inhibition, and is 600 thus under study for multiple clinical applications that include struggle against alcohol 601 addiction, cancer chemotherapy, treatment of copper-related disorders and anti-viral 602 treatment for hepatitis C and Human Immunodeficiency Virus (71). Here, we describe 603 a new possible clinical application of DSF in DS cognition through its effect on CBS 604 overexpression. CBS clearly represents a new relevant therapeutic target for improving 605 DS cognition and DSF, as such, opens new therapeutic avenues in DS patients. 606
28
We also demonstrated that CBS interacts genetically with Dyrk1a, a well-known 607 therapeutic target for DS. Mutual relationships between DYRK1A and CBS were 608 shown previously, with decreased DYRK1A protein observed in the liver (Hamelet et 609 al. 2009 ) and increased expression observed in the brain of Cbs +/mice (Planque et 610 al. 2013), while overexpression (or under-expression) of DYRK1A induce accumulation 611 (or reduction) of CBS expression in the liver (72). In order to explore the genetic 612 interactions between DYRK1A and CBS, we overexpressed Dyrk1a in the Dp1Yah 613 context by combining the Tg(Dyrk1a) and the Dp1Yah mice. Surprisingly, this 614 experiment restored the object recognition deficit observed in the Dp1Yah mouse 615 model but neither the increased locomotor activity in the open-field or the Y maze, nor 616 the working and spatial memory deficits. Thus the compensation is restricted to a 617 specific cognitive function, recognition memory, which is defective in both TgDyrk1a 618 and Dp1Yah models. Why this dosage effect is restricted to recognition memory 619 remains speculative. We may hypothesize that Cbs and Dyrk1a overdosage only 620 interact in specific regions of the adult brain involved in object discrimination explaining 621 why the increased locomotor activity and the working and visuo-spatial phenotypes 622 induced in Tg(Dyrk1a) animals are not affected. Alternatively, objects recognition 623 deficit is likely to result from an impact of DYRK1A on adult brain function while the 624 other phenotypes are the result of an impact during earlier stage of brain development. 625
On the one hand, object recognition has been shown to require undamaged 626 hippocampal perforant path connecting ento/perirhinal cortex with the dentate gyrus 627 for long retention intervals (> 15 min) in rat (73-78). On the other hand, synaptic 628 exchanges between the median prefrontal cortex (mPFC) and the hippocampus seems 629 to be sufficient to support the processing of short-term memory such as working 630 memory observed in the Y maze (79, 80) and hyperactivity is associated with the 631 29 prefrontal cortex, basal ganglia and cerebellum (81-84). Moreover, long-term 632 recognition memory has been shown to appear in the rat at weaning (post-natal day 633 21 in the mouse), (85), a period corresponding to the end of neurogenesis and 634 synaptogenesis in the dentate of the hippocampus, and reflecting the general 635 observation of 'infantile amnesia' observed on long-term memory tasks but not on 636 short-term memory ability (86). 637
Our proposal go farther than the demonstration by Zhang et al (23) that the 638 Hsa21 homologous region on the Mmu17 is a key determinant cognitive deficits in DS 639 mouse models. We showed here that CBS is a key gene for DS related phenotypes in 640 mice with the other homologous interval Cbr3-Fam3b located on Mmu16, 641 encompassing Dyrk1a. We should also consider that in people with DS, both genes 642 are trisomic and thus the recognition memory deficit observed in DS persons and in 643 the complete T21 mouse model (87) certainly depends not only on the interplay 644 between DYRK1A and CBS but also on interaction with other Hsa21 genes that may 645 affect different pathways or different parts of the brain. 646
The molecular mechanisms involved in Cbs-Dyrk1a genetic interaction have 647 been investigated through a quantitative proteomic approach. Although limited due to 648 the complexity of the hippocampus, the results highlight proteins networks interactions 649 between the two trisomic regions. 208 proteins were found deregulated, corresponding 650 to 148 GO categories and pathways, with 72 specific to Dp1Yah (out of 121) and 9 to 651
Dyrk1a transgenic model (out of 32; Supplementary table 3) and 5 common to both 652 Dp1Yah and Tg(Dyrk1a). More interestingly, GO terms such as cortical cytoskeleton 653 or cytoskeletal protein binding were respectively affected in Dp1Yah and in the 654 Tg(Dyrk1a) but were restored in the double transgenic animals, unravelling somehow 655 30 the nature of the pathways controlled by the epistatic interaction between CBS and 656 DYRK1A overdosage. DYRK1A is found mainly associated to and modulates the actin 657 cytoskeleton (88). CBS is the major enzyme involved in H2S production in the central 658 nervous system (67). Interestingly increase of H2S activates RAC1 leading to 659 rearrangement of actin cytoskeleton during endothelial cell migration (89). Thus a 660 simple hypothesis would be that the overdosage of CBS will lead to increased H2S 661 production and further activation of RAC1 with effect on actin cytoskeleton 662 rearrangement, a key mechanism involved in synaptic transmission. Remarkably 663 DYRK1A interacts with p120-Catenin-Kaiso and can then modulate Rac1 (90). Thus 664 one working hypothesis is based on CBS and DYRK1A pathways connected through 665
RAC1. 666
DYRK1A is the main driver of defects in DS mouse models for the homologous 667 region to Hsa21 located on Mmu16 (55). Based on study done in DS models for the 668 Mmu16 homologous region (91), DYRK1A has been selected as a drug target. As 669 reported previously, a treatment with epigallocatechin-3-gallate (EGCG), an inhibitor 670 of DYRK1A kinase activity, can restore some cognitive aspects found altered in people 671 with DS but the gain was limited (92, 93) . Nevertheless our results, by adding CBS to 672 the limited number of DS therapeutic targets, may improve the efficiency of DS 673 treatment, in particular by combining multiple therapies for improving the life of DS 674 patients. Finally, an important point to emphasize is that, for DYRK1A as well as for 675
CBS, both loss of function mutations and overdosage lead to intellectual deficiencies. 676
This is important to keep in mind when considering pharmacological intervention that 677 aims at inhibiting one or the other, or both, of these enzymes. Therefore, drug 678 treatment that lead to only a mild inhibition of CBS and/or DYRK1A should be favoured. 679 
